These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26040548)

  • 21. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
    Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR
    Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
    J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasminogen Activation System in Rectal Adenocarcinoma.
    Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
    Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
    Illemann M; Bird N; Majeed A; Laerum OD; Lund LR; Danø K; Nielsen BS
    Int J Cancer; 2009 Apr; 124(8):1860-70. PubMed ID: 19123477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
    Rabbani SA; Gladu J
    Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
    Tang CH; Hill ML; Brumwell AN; Chapman HA; Wei Y
    J Cell Sci; 2008 Nov; 121(Pt 22):3747-56. PubMed ID: 18940913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
    Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
    Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
    Sato S; Kopitz C; Grismayer B; Beaufort N; Reuning U; Schmitt M; Luther T; Kotzsch M; Krüger A; Magdolen V
    Breast Cancer Res Treat; 2011 Jun; 127(3):649-57. PubMed ID: 20635136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
    Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
    Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
    Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
    Cozzi PJ; Wang J; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y
    Hum Pathol; 2006 Nov; 37(11):1442-51. PubMed ID: 16949925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.